The 6-Month RR-TB Trial the FDA Should Be Studying as a Pragmatic Design Blueprint
- A recent New England Journal of Medicine (NEJM) pragmatic trial tested a 6-month rifampicin-resistant tuberculosis (RR-TB) regimen, establishing a new benchmark for adaptive evidence generation.
- The trial embedded randomization directly into existing treatment infrastructure to bypass the lengthy 18-month site qualification and rigid eligibility criteria typical of conventional Phase 3 development.
- This approach addresses a critical public health crisis, as the WHO Global Tuberculosis Report 2025 estimates 390,000 new MDR/RR-TB cases annually and 150,000 drug-resistant TB deaths in 2024.
- The study serves as a blueprint for the FDA to adopt pragmatic designs that accelerate the delivery of life-saving treatments in resource-limited settings.
Sources & Citations
1 sourceMore Stories
Reuters Health News Summary
• Zealand Pharma received a positive recommendation from the European Union's Committee for Medicinal Products for Human Use on Friday for its drug candidate Zeydovio. • The drug is designed to treat short bowel syndrome, a condition where the intestines are too short to absorb enough nutrients.
Read original · bundle.appCiting Replimune approval, experts say localized cancer meds could redefine care - NewsBreak
• Replimune received approval for Tudriqev, a medication delivered directly to tumors to treat cancer. • This localized delivery approach is also used by Amgen’s Imlygic to target therapeutics specifically at tumor sites.
Read original · newsbreak.comCue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria
• Cue Biopharma announced positive results from a Phase 2 clinical trial of its CUE-221 treatment for chronic spontaneous urticaria, a condition causing chronic hives. • The trial results demonstrated that the drug achieved significant efficacy and maintained a favorable safety profile for patients.
Read original · quiverquant.comMedical News
• Clinicians are raising alarms over the sale of direct-to-consumer emergency kits that contain prescription drugs and antibiotics. • These kits allow individuals to purchase potent medications without a doctor's oversight or a valid prescription.
Read original · archive.liMedicine News
• A survey of Alberta healthcare workers revealed that many staff members experienced coercion and moral injury resulting from COVID-19 vaccine mandates. • The findings highlight the psychological impact on medical professionals who felt forced to comply with mandates to maintain their employment.
Read original · archive.isWhat went right this week: the good news that matters - Positive News
• The World Health Organization recognized a historic achievement in the global effort to stop dog-transmitted rabies through vaccination and surveillance. • WHO Director General Tedros Adhanom Ghebreyesus credited the success to more than five decades of sustained investment in public health.
Read original · positive.news
Positive NewsReuters Health News Summary
• Xenon Pharmaceuticals paused new patient enrollment in clinical trials for its experimental major and bipolar depression drug on Thursday. • The company halted the studies following reports of side effects related to the mental and nervous system.
Read original · bundle.appGlobal health update: September 16, 2026
• The World Health Organization reported on September 10 that the Democratic Republic of the Congo is experiencing the fastest-growing Ebola outbreak on record. • Health officials have confirmed more than 6,700 cases and more than 3,200 deaths during this current surge.
Read original · bushcenter.org
George W. Bush Presidential CenterRFK Jr. Children's Health Defense, NIH grants: Morning Rounds
• Robert F. Kennedy Jr. is scheduled to speak at a conference hosted by the Children's Health Defense organization. • The event is part of a broader series of health news updates including research on protecting heart health in outer space.
Read original · statnews.com
StatnewsThe Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done. - KFF Health News
• The FDA has allowed companies to sell drugs and devices while completing safety and efficacy studies, but many of these postmarket requirements are now overdue or behind schedule. • FDA leaders announced in February that the default requirement for agency approvals will shift to one clinical trial instead of two.
Read original · kffhealthnews.org
KFF Health NewsFour measles deaths, a looming policy comment deadline, and how to read a study: The State of US Vaccine Policy
• The U.S. Food and Drug Administration approved this season's COVID vaccines nearly three weeks ago for general use. • Children with private insurance can currently access the shots, but those in the Vaccines for Children program must wait for Health and Human Services sign-off.
Read original · cidrap.umn.eduPhiladelphia health officials report a measles exposure at CHOP
• Philadelphia health officials reported a potential measles exposure at the Children's Hospital of Philadelphia on September 11. • The exposure occurred in the neonatal intensive care unit and other locations at the hospital's 3401 Civic Center Blvd facility.
Read original · inquirer.com